Anti-venom Market: Growing Incidence of Venomous Snakebites to Drive Market Growth


The global Anti-venom Market is estimated to be valued at US$ 504.9 Mn in 2018 and is expected to exhibit a CAGR of 4.7% over the forecast period of 2018-2026, according to Coherent Market Insights.

Market Overview:

Anti-venom is a biological product used to treat snakebite envenomation. It works by neutralizing the venom toxins and preventing their harmful effects on the body. The global anti-venom market is driven by the growing incidence of venomous snakebites, especially in regions with high snake populations. Snakebites can cause serious health complications and even death if left untreated, creating a need for effective anti-venom products. The market offers a range of anti-venom products derived from various sources, such as equine, ovine, and recombinant technologies. These products provide quick and accurate treatment options for snakebite victims, reducing morbidity and mortality rates associated with snakebites.

Market Key Trends:

One key trend in the anti-venom market is the increasing focus on research and development activities to develop advanced anti-venom formulations. Manufacturers are investing in the development of new technologies and innovative approaches to enhance the efficacy and safety profiles of anti-venom products. The use of recombinant DNA technology is gaining traction in the market, as it allows the production of anti-venom with improved specificity and reduced adverse reactions. Additionally, strategic collaborations and partnerships among key players are being observed to accelerate product development and geographical expansion. These trends are expected to drive market growth and offer better treatment options for snakebite victims in the coming years.
Porter’s Analysis

Threat of new entrants: The threat of new entrants in the anti-venom market is relatively low. This is due to high barriers to entry, such as the need for extensive research and development capabilities, complex manufacturing processes, strict regulatory requirements, and the need for significant investment in infrastructure and distribution networks.

Bargaining power of buyers: The bargaining power of buyers in the anti-venom market is moderate. While buyers have a range of options to choose from, the life-saving nature of anti-venom drugs limits their negotiation power. Additionally, the low number of suppliers and the fragmented nature of the market give some leverage to the buyers.

Bargaining power of suppliers: The bargaining power of suppliers in the anti-venom market is high. The limited number of suppliers and the specialized expertise required in producing anti-venom drugs give suppliers significant bargaining power. Suppliers can dictate prices and terms to a certain extent, especially in regions where there is a scarcity of effective anti-venom products.

Threat of new substitutes: The threat of new substitutes in the anti-venom market is low. Anti-venom drugs are the primary treatment option for envenomation, and there are no widely accepted alternatives. Although other treatments and therapies are being researched, their effectiveness and availability are limited.

Competitive rivalry: The competitive rivalry in the anti-venom market is intense. The market is highly fragmented, with numerous small and large players competing for market share. Key players are investing in research and development activities to develop new and more effective anti-venom therapies, leading to intense competition and price pressures.

Key Takeaways

The global Anti-Venom Market Demand is expected to witness high growth, exhibiting a CAGR of 4.7% over the forecast period (2018-2026). This growth can be attributed to increasing snakebite incidents in several regions, particularly in developing countries with high snakebite mortality rates. Rising awareness about snakebites and the importance of timely treatment is driving the demand for anti-venom products.

Regional analysis shows that Asia Pacific is the fastest-growing and dominating region in the anti-venom market. The region has a high prevalence of venomous snakes, leading to a significant number of snakebite cases. Additionally, the lack of access to proper healthcare facilities and anti-venom products in rural areas further contributes to the demand for anti-venom drugs in this region.

Key players operating in the anti-venom market include BTG plc., Laboratorios Silanes, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., and Rare Disease Therapeutics Inc. These players are focusing on developing advanced anti-venom therapies, expanding their distribution networks, and entering into strategic partnerships to strengthen their market position.

Leave a reply